32 results
Thumbnail

D1.309 - Association of Antenatal Corticosteroids with Risk of Autoimmune Diseases in Children: a Nationwide Cohort Study

Thumbnail

D1.308 - Case report: challenges in a long-term prophylaxis in hereditary angioedema (HAE)

Thumbnail

D1.310 - Phenotypes of patients with Hereditary Angioedema (HAE): a case series

Thumbnail

D1.311 - Treatment Dilemmas in CARMIL2 Deficiency

Thumbnail

D1.312 - Acquired C1-inhibitor deficiency angioedema treated with lanadelumab: a case series

Thumbnail

D1.313 - Inborn Error of Immunity Associated Inflammatory Bowel Disease at a Tertiary Care Center

Thumbnail

D1.315 - Classifying the unclassifiable: diagnosis, characterization, and management of adults with unclassified primary antibody deficiency (unPAD)

Thumbnail

D1.316 - Lessons Learned from the Diagnosis and Management of a female pediatric patient with NCF2 Mutations and Chronic Granulomatous Disease

Thumbnail

D1.317 - A Retrospective Analysis of Dengue-Associated Hemophagocytic Lymphohistiocytosis in a Dengue-Endemic Country

Thumbnail

D1.318 - Extending Lanadelumab Dosing Intervals to Every 4 Weeks With Sustained Effectiveness for Hereditary Angioedema Attack Prevention: An Analysis From the Final ENABLE Study Data

Thumbnail

D1.319 - The Silent Threat of Hereditary Angioedema in Children: Single Center Experience

Thumbnail

D1.322 - A Prescription for Lower Immunity: The Hidden Cost of Certain Psychiatric Medications

Thumbnail

D1.323 - Concurrence of essential mixed cryoglobulinemia and cold agglutinin disease: a matter of shared light chains. Case series and literature review

Thumbnail

D1.324 - Evaluation of the Potential for Sebetralstat to Cause Pseudo-allergic Reactions

Thumbnail

D1.325 - Autoantibodies to interferon-gamma: clinical features, treatment outcomes, and in-vitro monitoring of disease

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates